Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.